Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation

An intravascular ultrasound analysis

Young Joon Hong, Myung Ho Jeong, Sun Ho Hwang, Nam Sik Yun, Sang Yeob Lim, Sang Rok Lee, Seo Na Hong, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Weon Kim, Young Keun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Smaller postprocedural minimum stent areas (MSA) measured by intravascular ultrasound (IVUS) have been associated with higher restenosis rates. Methods: This was a single-center, prospective, randomized trial and we assessed the predictive value of MSA for long-term patency and the incidence and extent of incomplete stent apposition (ISA) following abciximab-coated stent (n = 69) compared to bare metal stent (BMS) implantation (n = 69). All patients underwent IVUS follow-up at 6 months. Results: At follow-up coronary angiogram, the restenosis rate and late loss were 12%, 0.30 ± 0.24 mm in abciximab-coated stent group and 29%, 0.68 ± 0.36 mm in BMS group (p = 0.011, 0.010, respectively). At follow-up IVUS, intrastent lumen area was significantly larger and intrastent neointimal hyperplasia area was significantly smaller in abciximab-coated stent group than those in BMS group (5.9 ± 1.6 mm2 vs. 4.5 ± 1.7 mm2, p = 0.001, and 1.9 ± 1.5 mm2 vs. 3.3 ± 1.9 mm2, p < 0.001, respectively). Target lesion revascularization occurred in 9%, 0%, and 0% in abciximab-coated stent group and 19%, 4%, and 1% in BMS group in lesions with a MSA < 6.0 mm2, from 6 to 7.5 mm2, and > 7.5 mm2, respectively. Late-acquired ISA at follow-up was observed in 7 patients and there was no difference in the incidence of ISA between both groups [abciximab-coated stent: n = 3 (4%) vs. BMS: n = 4 (6%), p = 0.698]. Conclusion: Abciximab-coated stent reduced restenosis and had a considerably lower optimal MSA threshold compared to BMS and showed lower incidence of late-acquired ISA.

Original languageEnglish
Pages (from-to)23-28
Number of pages6
JournalInternational Journal of Cardiology
Volume123
Issue number1
DOIs
Publication statusPublished - 2007 Dec 15
Externally publishedYes

Fingerprint

Stents
Metals
abciximab
Incidence
Coronary Restenosis
Hyperplasia
Angiography

Keywords

  • Coronary artery diseases
  • Intravascular ultrasound
  • Platelets
  • Stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation : An intravascular ultrasound analysis. / Hong, Young Joon; Jeong, Myung Ho; Hwang, Sun Ho; Yun, Nam Sik; Lim, Sang Yeob; Lee, Sang Rok; Hong, Seo Na; Kim, Kye Hun; Park, Hyung Wook; Kim, Ju Han; Kim, Weon; Ahn, Young Keun; Cho, Jeong Gwan; Park, Jong Chun; Kang, Jung Chaee.

In: International Journal of Cardiology, Vol. 123, No. 1, 15.12.2007, p. 23-28.

Research output: Contribution to journalArticle

Hong, YJ, Jeong, MH, Hwang, SH, Yun, NS, Lim, SY, Lee, SR, Hong, SN, Kim, KH, Park, HW, Kim, JH, Kim, W, Ahn, YK, Cho, JG, Park, JC & Kang, JC 2007, 'Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation: An intravascular ultrasound analysis', International Journal of Cardiology, vol. 123, no. 1, pp. 23-28. https://doi.org/10.1016/j.ijcard.2006.11.101
Hong, Young Joon ; Jeong, Myung Ho ; Hwang, Sun Ho ; Yun, Nam Sik ; Lim, Sang Yeob ; Lee, Sang Rok ; Hong, Seo Na ; Kim, Kye Hun ; Park, Hyung Wook ; Kim, Ju Han ; Kim, Weon ; Ahn, Young Keun ; Cho, Jeong Gwan ; Park, Jong Chun ; Kang, Jung Chaee. / Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation : An intravascular ultrasound analysis. In: International Journal of Cardiology. 2007 ; Vol. 123, No. 1. pp. 23-28.
@article{b5e9211538b64207a6b99d5dc1271d62,
title = "Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation: An intravascular ultrasound analysis",
abstract = "Background: Smaller postprocedural minimum stent areas (MSA) measured by intravascular ultrasound (IVUS) have been associated with higher restenosis rates. Methods: This was a single-center, prospective, randomized trial and we assessed the predictive value of MSA for long-term patency and the incidence and extent of incomplete stent apposition (ISA) following abciximab-coated stent (n = 69) compared to bare metal stent (BMS) implantation (n = 69). All patients underwent IVUS follow-up at 6 months. Results: At follow-up coronary angiogram, the restenosis rate and late loss were 12{\%}, 0.30 ± 0.24 mm in abciximab-coated stent group and 29{\%}, 0.68 ± 0.36 mm in BMS group (p = 0.011, 0.010, respectively). At follow-up IVUS, intrastent lumen area was significantly larger and intrastent neointimal hyperplasia area was significantly smaller in abciximab-coated stent group than those in BMS group (5.9 ± 1.6 mm2 vs. 4.5 ± 1.7 mm2, p = 0.001, and 1.9 ± 1.5 mm2 vs. 3.3 ± 1.9 mm2, p < 0.001, respectively). Target lesion revascularization occurred in 9{\%}, 0{\%}, and 0{\%} in abciximab-coated stent group and 19{\%}, 4{\%}, and 1{\%} in BMS group in lesions with a MSA < 6.0 mm2, from 6 to 7.5 mm2, and > 7.5 mm2, respectively. Late-acquired ISA at follow-up was observed in 7 patients and there was no difference in the incidence of ISA between both groups [abciximab-coated stent: n = 3 (4{\%}) vs. BMS: n = 4 (6{\%}), p = 0.698]. Conclusion: Abciximab-coated stent reduced restenosis and had a considerably lower optimal MSA threshold compared to BMS and showed lower incidence of late-acquired ISA.",
keywords = "Coronary artery diseases, Intravascular ultrasound, Platelets, Stents",
author = "Hong, {Young Joon} and Jeong, {Myung Ho} and Hwang, {Sun Ho} and Yun, {Nam Sik} and Lim, {Sang Yeob} and Lee, {Sang Rok} and Hong, {Seo Na} and Kim, {Kye Hun} and Park, {Hyung Wook} and Kim, {Ju Han} and Weon Kim and Ahn, {Young Keun} and Cho, {Jeong Gwan} and Park, {Jong Chun} and Kang, {Jung Chaee}",
year = "2007",
month = "12",
day = "15",
doi = "10.1016/j.ijcard.2006.11.101",
language = "English",
volume = "123",
pages = "23--28",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation

T2 - An intravascular ultrasound analysis

AU - Hong, Young Joon

AU - Jeong, Myung Ho

AU - Hwang, Sun Ho

AU - Yun, Nam Sik

AU - Lim, Sang Yeob

AU - Lee, Sang Rok

AU - Hong, Seo Na

AU - Kim, Kye Hun

AU - Park, Hyung Wook

AU - Kim, Ju Han

AU - Kim, Weon

AU - Ahn, Young Keun

AU - Cho, Jeong Gwan

AU - Park, Jong Chun

AU - Kang, Jung Chaee

PY - 2007/12/15

Y1 - 2007/12/15

N2 - Background: Smaller postprocedural minimum stent areas (MSA) measured by intravascular ultrasound (IVUS) have been associated with higher restenosis rates. Methods: This was a single-center, prospective, randomized trial and we assessed the predictive value of MSA for long-term patency and the incidence and extent of incomplete stent apposition (ISA) following abciximab-coated stent (n = 69) compared to bare metal stent (BMS) implantation (n = 69). All patients underwent IVUS follow-up at 6 months. Results: At follow-up coronary angiogram, the restenosis rate and late loss were 12%, 0.30 ± 0.24 mm in abciximab-coated stent group and 29%, 0.68 ± 0.36 mm in BMS group (p = 0.011, 0.010, respectively). At follow-up IVUS, intrastent lumen area was significantly larger and intrastent neointimal hyperplasia area was significantly smaller in abciximab-coated stent group than those in BMS group (5.9 ± 1.6 mm2 vs. 4.5 ± 1.7 mm2, p = 0.001, and 1.9 ± 1.5 mm2 vs. 3.3 ± 1.9 mm2, p < 0.001, respectively). Target lesion revascularization occurred in 9%, 0%, and 0% in abciximab-coated stent group and 19%, 4%, and 1% in BMS group in lesions with a MSA < 6.0 mm2, from 6 to 7.5 mm2, and > 7.5 mm2, respectively. Late-acquired ISA at follow-up was observed in 7 patients and there was no difference in the incidence of ISA between both groups [abciximab-coated stent: n = 3 (4%) vs. BMS: n = 4 (6%), p = 0.698]. Conclusion: Abciximab-coated stent reduced restenosis and had a considerably lower optimal MSA threshold compared to BMS and showed lower incidence of late-acquired ISA.

AB - Background: Smaller postprocedural minimum stent areas (MSA) measured by intravascular ultrasound (IVUS) have been associated with higher restenosis rates. Methods: This was a single-center, prospective, randomized trial and we assessed the predictive value of MSA for long-term patency and the incidence and extent of incomplete stent apposition (ISA) following abciximab-coated stent (n = 69) compared to bare metal stent (BMS) implantation (n = 69). All patients underwent IVUS follow-up at 6 months. Results: At follow-up coronary angiogram, the restenosis rate and late loss were 12%, 0.30 ± 0.24 mm in abciximab-coated stent group and 29%, 0.68 ± 0.36 mm in BMS group (p = 0.011, 0.010, respectively). At follow-up IVUS, intrastent lumen area was significantly larger and intrastent neointimal hyperplasia area was significantly smaller in abciximab-coated stent group than those in BMS group (5.9 ± 1.6 mm2 vs. 4.5 ± 1.7 mm2, p = 0.001, and 1.9 ± 1.5 mm2 vs. 3.3 ± 1.9 mm2, p < 0.001, respectively). Target lesion revascularization occurred in 9%, 0%, and 0% in abciximab-coated stent group and 19%, 4%, and 1% in BMS group in lesions with a MSA < 6.0 mm2, from 6 to 7.5 mm2, and > 7.5 mm2, respectively. Late-acquired ISA at follow-up was observed in 7 patients and there was no difference in the incidence of ISA between both groups [abciximab-coated stent: n = 3 (4%) vs. BMS: n = 4 (6%), p = 0.698]. Conclusion: Abciximab-coated stent reduced restenosis and had a considerably lower optimal MSA threshold compared to BMS and showed lower incidence of late-acquired ISA.

KW - Coronary artery diseases

KW - Intravascular ultrasound

KW - Platelets

KW - Stents

UR - http://www.scopus.com/inward/record.url?scp=36148977184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148977184&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2006.11.101

DO - 10.1016/j.ijcard.2006.11.101

M3 - Article

VL - 123

SP - 23

EP - 28

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -